FDA Approved: FIASP — Supplemental Application (Novo Nordisk)

View source ↗

Summary

The FDA approved a supplemental application for FIASP (insulin aspart injection) from Novo Nordisk, authorizing changes to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Fiasp (insulin aspart)

Snippet

SUPPL AP for FIASP (INSULIN ASPART INJECTION)